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Available online 27 May 2016Acrylamide is a well-known neurotoxic compound and people get exposed to the compound by food consump-
tion and environmental pollutants. Since acrylamide crosses the placenta barrier, the fetus is also being exposed
resulting in a risk for developmental neurotoxicity. In this study, theneural progenitor cell line C17.2 and the neu-
roblastoma cell line SH-SY5Ywere used to study proliferation and differentiation as alerting indicators for devel-
opmental neurotoxicity. For both cell lines, acrylamide reduced the number of viable cells by reducing
proliferation and inducing cell death in undifferentiated cells. Acrylamide concentrations starting at 10 fM atten-
uated the differentiation process in SH-SY5Y cells by sustaining cell proliferation and neurite outgrowth was re-
duced at concentrations from 10 pM. Acrylamide signiﬁcantly reduced the number of neurons starting at 1 μM
and altered the ratio between the different phenotypes in differentiating C17.2 cell cultures. Ten micromolar of
acrylamide also reduced the expression of the neuronal and astrocyte biomarkers. Although the neurotoxic con-
centrations in the femtomolar range seem to be speciﬁc for the SH-SY5Y cell line, the fact that micromolar con-
centrations of acrylamide seem to attenuate the differentiation process in both cell lines raises the interest to
further investigations on the possible developmental neurotoxicity of acrylamide.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Acrylamide is a water-soluble, vinyl monomer that has various
applications in the chemical industry for water management, dye
synthesis, in textile additives and in paint softeners as well as in
the cosmetic industry (IARC, 1994). Acrylamide can also be generat-
ed from food components during heat treatment as a result of the
Maillard reaction between amino acids (mainly asparagine) and re-
ducing sugars or reactive carbonyls (Mottram et al., 2002). Most peo-
ple are exposed to acrylamide through food consumption and
environmental pollutants (Kutting et al., 2009). Studies on exposed
human populations and laboratory animals have shown that acryl-
amide can be absorbed orally, dermally, and by inhalationfactor; BrdUrd, 5-bromo-2′-
2, Dulbecco's modiﬁed Eagles
ide; GFAP, glial ﬁbrillary acidic
yl-tetrazolium bromide; NGF,
, propidium iodide; TBP, TATA-
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vist), stina.oredsson@biol.lu.se
. This is an open access article under(Dearﬁeld et al., 1988, Sumner et al., 2003). Regardless of the absorp-
tion route, acrylamide is distributed throughout the body. The tis-
sues that are the most susceptible to acrylamide exposure include
liver, kidney, smooth and skeletal muscles and the nervous system
(Miller et al., 1982). Animal studies have shown that the polymeric
form of acrylamide is non-toxic but the monomeric form induces
neurotoxicity, reproductive toxicity, genotoxicity and carcinogenici-
ty (Chapin et al., 1995, Dearﬁeld et al., 1995). However, only
acrylamide-induced neurotoxicity has been documented in occupa-
tionally exposed populations in humans, indicating implications in
human health (Kjuus et al., 2004). Acrylamide has been recognized
as a neurotoxic substance since the 1950s when it was realized that
occupational exposure could give rise to cumulative neurotoxicity
characterized by ataxia, skeletal muscle weakness, cognitive impair-
ment, and numbness of the extremities (Garland and Patterson,
1967). It has been shown in animals, as well as in tissue- and cell
cultures that the monomeric form of acrylamide gives rise to similar
neurotoxic effects as seen in exposed human populations
(McCollister et al., 1964, Miller and Spencer, 1985). It has been sug-
gested that the acrylamide-induced neurotoxicity is mediated
through axonopathy in both central and peripheral nervous system
caused by initial distal nerve terminal damage and subsequent retro-
grade axon degeneration (LoPachin, 2002).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to be exposed in utero is obvious. Acrylamide has also been detected in
breast milk, indicating that acrylamide exposure may continue during
infancy (Sörgel et al., 2002, von Stedingk et al., 2011). Prenatal and peri-
natal exposure to acrylamide decreases the average horizontal motor
activity and auditory startle response in exposed rats (Wise et al.,
1995). Furthermore, acrylamide disrupts the development of cerebel-
lum and induces lipid peroxidation and oxidative stress in the develop-
ing medulla oblongata in rats (Allam et al., 2013).
The number of children being diagnosed with learning and
neurodevelopmental disorders has increased over the past three de-
cades (US EPA, 2015). Hence, there is an emerging need to develop
and validate robust methods that are capable to alert for chemicals
that may induce neurodevelopmental toxicity. Also, many neurodegen-
erative disorders including Parkinson's disease, Alzheimer's disease
and amyotrophic lateral sclerosis, are in fact believed to be
neurodevelopmental diseases because they share common pathophys-
iological cascades involving oxidative stress and impaired hippocampal
neurogenesis in mice (Park et al., 2010). Since acrylamide has a nerve
terminal speciﬁc site of action and can compete for the cysteine binding
sites of nucleophilic scavengers, it has been suggested that
neuropathogenic processes could be accelerated by acrylamide
(LoPachin et al., 2008). Here, we have studied features of developmental
neurotoxicity of acrylamide using mechanistic endpoints during prolif-
eration and different stages of neuronal differentiation in the murine
neural progenitor cell line C17.2 and the human neuroblastoma cell
line SH-SY5Y.
2. Materials and methods
2.1. Chemicals and reagents
Acrylamide (99.9% purity) (A9099), putrescine dihydrochloride
(P5780), progesterone (P8783), sodium selenite (S5261), bovine insu-
lin (I1882), all-trans-retinoic acid (R2625), dimethyl sulfoxide
(DMSO) (D4540), bovine serum albumin (BSA) (A2153), NP-40 and
agar were purchased from Sigma Aldrich (Sweden). Recombinant
mouse β-nerve growth factor (NGF) (1156-NG) and recombinant
human brain-derived neurotrophic factor (BDNF) (248-BD) were pur-
chased from R&D systems (United Kingdom). Apo-transferrin from bo-
vine plasma (02,152,334)waspurchased fromMPBiomedicals. GIBCO®
phosphate-buffered saline (PBS), GIBCO® Trypsin/ EDTA (0.05/0.02%),
GIBCO® Dulbecco's modiﬁed Eagles medium (DMEM), GIBCO®
Dulbecco's modiﬁed Eagles medium:Nutrient mixture F-12 (DMEM/F-
12), GIBCO® minimum essential medium (MEM), GIBCO® MEM non-
essential amino acid solution, horse serum, fetal calf serum, GIBCO® L-
glutamine, GIBCO® Penicillin, 10,000 U/mL and streptomycin,
10,000 μg/mL, RevertAid ™ H Minus First Strand cDNA Synthesis Kit
(K1621), RiboRuler High Range RNA Ladder, 3-[4,5-Dimethylthiazol-2-
yl]-2,5 diphenyl-tetrazolium bromide (MTT), Horseradish Peroxidase-
conjugated Anti-Goat IgG (31,402), DRAQ5, Anti-rabbit antibody conju-
gated with Alexa Fluor 488, SouthernBiotech Fluoromount-G™ and
Maxima® SYBR Green/Fluorescein qPCR Master Mix were purchased
from ThermoFisher Scientiﬁc (Sweden). RNA extraction kit RNeasy
Plus Mini Kit was purchased from Qiagen. All primers for the Real-
Time Reverse Transcription quantitative Polymerase Chain Reaction
(RT-qPCR) were purchased from Euroﬁns MWG (Germany). All plastic
ware used for cell culturing were purchased from Corning Inc. Antibod-
ies against glial ﬁbrillary acidic protein (GFAP) (ab7260) for western
blot and βIII-tubulin (ab18207) for western blot and immunoﬂuores-
cencewere purchased fromAbcam (United Kingdom). Antibody against
GFAP for immunoﬂuorescence (Z033429-2) was purchased from Dako
(Denmark). Antibody against β-actin (sc-1616) was purchased from
Santa Cruz Biotechnology Inc. (USA). Horseradish peroxidase-conjugat-
ed anti-rabbit IgG (NA934V) was purchased from GE Healthcare Life
Sciences (Sweden). Bio-Rad protein assay (500-0006) was purchasedfrom Bio-Rad. [Methyl-3H]-thymidine (NET027A001MC), Filtermat A
(1450-421) and Ultima Gold XR (6013111) were purchased from
PerkinElmer (USA). Scintillation vials (KART933) were purchased
from VWR International (USA). 5-Bromo-2′-deoxyuridine (BrdUrd)
and propidium iodide (PI) were purchased from Sigma, (USA). The an-
tibody against BrdUrd (M744) and the secondary-FITC-conjugated anti-
body (F3213) were purchased from Dakopatts (Denmark).
2.2. Cell lines
Chemicals can give rise to different toxicological effects depending
on what cell model they are tested in. Therefore, we chose to study
the effect of acrylamide on neuronal differentiation as indication of de-
velopmental neurotoxicity in two different cell lines. Themurine neural
progenitor cell line C17.2 (Snyder et al., 1992) was a generous gift from
Professor Sandra Ceccatelli (Karolinska Institute, Stockholm, Sweden)
with permission of Professor Evan Snyder (Harvard Medical School,
Boston, USA). The C17.2 cell line is a multipotent progenitor cell line
that can differentiate into neurons and glia cells as a mixed cell popula-
tion (Lundqvist et al., 2013).
The human neuroblastoma SH-SY5Y cell line (Biedler et al., 1978)
has been shown to be a very useful model system to study neuronal dif-
ferentiation and function (Agholme et al., 2010). The SH-SY5Y cells de-
velop into a neuronal-like phenotype upon differentiation with all-
trans-retinoic acid (Påhlman et al., 1990).
2.3. Cell culturing
For routine cultures, the C17.2 cells were seeded at a density of
1.27 × 103 cells/cm2 in cell culture Petri dishes. They were cultured in
DMEM supplemented with 5% horse serum, 10% fetal calf serum,
2 mM L-glutamine, 100 U penicillin/mL and 100 μg streptomycin/mL.
The conﬂuent cells were detached every 3rd and a half day using 0.05/
0.02% trypsin/EDTA and seeded in a new cell culture Petri dish at the
original density. For differentiation studies, the C17.2 cells were seeded
in routine culture medium (see individual experiment for density).
Twenty-four hours after seeding the medium was changed to DMEM/
F-12 medium supplemented with 1 mM L-glutamine, 100 U penicillin/
mL, 100 μg streptomycin/mL, modiﬁed N2 supplements (to a ﬁnal con-
centration of 5 μg/mL bovine insulin, 20 nM progesterone, 30 nM sodi-
um selenite, 100 μg/mL bovine apo-transferrin, and 100 μM putrescine
dihydrochloride), 10 ng/mL NGF and 10 ng/mL BDNF. The differentia-
tion medium was changed every 3rd day for the duration of the
differentiation.
For routine cultures, the SH-SY5Y cells were seeded at a density of
27× 103 cells/cm2 in cell cultureﬂasks. Theywere cultured inMEMsup-
plemented with 10% fetal calf serum, 1% non-essential amino acids,
2 mM L-glutamine, 100 μg streptomycin/mL, 100 U penicillin/mL. The
conﬂuent cells were detached once a week using 0.05/0.02% trypsin/
EDTA and seeded in a new cell culture ﬂask at the original density. For
differentiation studies, the SH-SY5Y cells were seeded in routine culture
medium (see individual experiment for density). Twenty-four hours
after seeding themediumwas changed to DMEM/F-12medium supple-
mentedwith 1mML-glutamine, 100U penicillin/mL, 100 μg streptomy-
cin/mL, modiﬁed N2 supplements as described above and 1 μM of all-
trans-retinoic acid. The differentiation medium was changed every 3rd
day for the duration of the differentiation. Both cell lines were kept in
a humidiﬁed atmosphere of 5% CO2 in air at 37 °C.
2.4. Acrylamide exposure
Acrylamidewas dissolved in the culture medium used for the differ-
ent experiments. Before addition to the cells, the acrylamide stock solu-
tion was sterile-ﬁltered through a 0.2 μm ﬁlter and then diluted to
different concentrations ranging from 1 fM to 2 mM. Cell cultures ex-
posed to medium without acrylamide were used as a control. For all
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together with the change of the culture medium (change to differentia-
tion medium for the differentiation studies and replacement to fresh
routine culture medium for proliferation studies). Acrylamide was
added at every change ofmedium throughout the duration of the exper-
iment. Fresh medium without acrylamide was added to control cells. A
fresh stock solution of acrylamidewas prepared right before addition to
the cells for each exposure time.
Exposure time and concentrations differs between the two cell lines.
Since the C17.2 cells aremultipotent progenitor cells and hence, display
a more immature starting point than the SH-SY5Y cells, the C17.2 cells
were differentiated for 6 and 10 days while the SH-SY5Y cells were
only differentiated for 3 and 6 days. The two time periods of differenti-
ation for each cell line were chosen to reﬂect two different time win-
dows of neuronal development.
2.5. Growth curve experiments
The C17.2 cells were seeded in routine culture medium in 10 cm di-
ameter cell culture Petri dishes at a density of 1.27 × 103 cells/cm2. The
SH-SY5Y cells were seeded in routine culture medium at a density of
27 × 103 cells/cm2 in cell culture Petri dishes with a diameter of 6 cm.
For both cell lines, the cells were exposed to 10, 100 and 1000 μMof ac-
rylamide for 24, 48 and 72 h. The cells were detached using 0.05/0.02%
trypsin/EDTA and counted in a Bürker chamber using a phase contrast
microscope.
2.6. 5-Bromo-2′-deoxyuridine cell proliferation assay
The C17.2 cells were seeded in routine culture medium at a density
of 1.27 × 103 cells/cm2 in cell culture Petri dishes with a diameter of
6 cm. The SH-SY5Y cells were seeded in routine culture medium at a
density of 27 × 103 cells/cm2 in cell culture Petri dishes with a diameter
of 6 cm. For both cell lines, the mediumwas changed 24 h after seeding
and the cells were simultaneously exposed to acrylamide concentra-
tions ranging between 1–1000 μM. The C17.2 cells were exposed for
3 days and the SH-SY5Y cells were exposed for 3 and 6 days. The
C17.2 cells were exposed for 3 days since they cannot be kept in culture
for a longer period of time without spontaneously differentiating. One
hour before harvesting, BrdUrd was added to a ﬁnal concentration of
5 μM. The cells were detached using 0.05/0.02% trypsin/EDTA, centri-
fuged for 5 min at 4 °C at 600 g and the pellet was resuspended in
1mL of 70% ice-cold ethanol and stored at−20 °C until further analysis.
The cells were prepared for analysis of DNA and BrdUrd contents ac-
cording to Fredlund et al. (1994). In short, the cells were incubated in
a pepsin solution to isolate cell nuclei and partially degrade chroma-
tin-associated proteins. To allow access of the primary BrdUrd antibody
to BrdUrd incorporated into DNA, theDNAwas then partially denatured
by incubating the cells in 2 M HCl. A secondary FITC-conjugated anti-
body was used to detect the primary antibody. The double-stranded re-
gions of DNA were then stained with PI. The nuclei were analyzed with
respect to DNA content (red ﬂuorescence from PI) and BrdUrd (green
ﬂuorescence from FITC) in a BD Accuri C6 ﬂow cytometer (BD Biosci-
ences) and analyzed using the MultiCycle® software (Phoenix Flow
Systems). After gating of nuclei in a PI ﬂuorescence area versus height
cytogram to exclude doublets, the DNA versus BrdUrd cytogram was
displayed. Three regions were set in the cytogram: one around the
total population, one around the BrdUrdnegative nuclei and one around
the BrdUrd positive nuclei. The data were used to calculate the percent-
age of BrdUrd positive cells for each sample.
2.7. Flow cytometric analysis of Sub-G1 region of the DNA histogram
The C17.2 cells were seeded in routine culture medium at a density
of 1.27 × 103 cells/cm2 in cell culture Petri dishes with a diameter of
6 cm. The SH-SY5Y cells were seeded in routine culture medium at adensity of 27 × 103 cells/cm2 in cell culture Petri dishes with a diameter
of 6 cm. For both cell lines, the mediumwas changed 24 h after seeding
and the cells were simultaneously exposed to acrylamide concentra-
tions ranging between 1 and 1000 μM. The C17.2 cells were exposed
for 3 days and the SH-SY5Y cells were exposed for 3 and 6 days. The
C17.2 cells were exposed for 3 days only since they cannot be kept in
culture for a longer period of time without spontaneously differentiat-
ing. The cells were detached using 0.05/0.02% trypsin/EDTA and pooled
with detached cells ﬂoating in the medium. The cells were centrifuged
for 5 min at 4 °C at 600 g and the pellet was resuspended in 1 mL of
70% ice-cold ethanol and stored at−20 °C until further analysis. The
cells were washed in 10 mL of PBS, pelleted and resuspended in PBS
containing 100 μg/mL PI, 0.6% NP-40 and 100 μg/mL ribonuclease A.
The cell nuclei were analyzed in a BD Accuri C6 ﬂow cytometer (BD Bio-
sciences) and analyzed using the MultiCycle® software (Phoenix Flow
Systems). After gating of nuclei in a PI ﬂuorescence area versus height
cytogram to exclude doublets, the DNA histogram including the sub-
G1 region with signals from dead cells was displayed. A region was set
around all signals in the histogram and another region around the
sub-G1/G0 signals i.e. not including the proper DNA histogram of G1/
G0, S, and G2 cells. M phase cells are not included in the assay since
they do not contain a nuclear membrane and are removed by the PI
staining solution when the cell membrane is disrupted. The data were
then used to calculate the percentage sub-G1 signals, which is a repre-
sentation of cell death.
2.8. Number of viable cells
The number of viable cells was measured using the MTT assay
(Mosmann, 1983). For all experiments, the cells were seeded in 96-
well plates. For viability studies in undifferentiated neural progenitor
cells, the C17.2 cells were seeded at a density of 1.27 × 103 cells/cm2
and the SH-SY5Y cells were seeded at a density of 27 × 103 cells/cm2.
Acrylamide was added 24 h after seeding to a ﬁnal concentration be-
tween 1 and 2000 μM. The C17.2 cells were exposed for 3 days and
the SH-SY5Y cells were exposed for 3 and 6 days. The C17.2 cells were
exposed for 3 days only since they cannot be kept in culture for a longer
period of time without spontaneously differentiating.
To examine the number of viable cells after exposure to differentiat-
ing cells, C17.2 cellswere seeded at a density of 3.75× 103 cells/cm2 and
SH-SY5Y cellswere seeded at a density of 12.5× 103 cells/cm2. Acrylam-
ide was added in differentiation medium 24 h after seeding, in a range
between 1 nM and 1 mM for C17.2 cultures and from 10 fM to 1 mM
for SH-SY5Y cultures. The C17.2 cells were exposed for 6 and 10 days
and the SH-SY5Y cells were exposed for 3 and 6 days during differenti-
ation. After the desired exposure time, 10 μL of 0.5 mg/mLMTT solution
in PBSwere added to eachwell. The platewas incubated in a humidiﬁed
atmosphere of 5% CO2 in air at 37 °C for 1 h. After 1 h, the mediumwas
carefully removed and the formazan crystalswere dissolved in 100 μL of
DMSOwhile placed on a shaker. The formazan dye product was quanti-
ﬁed with Sunrise™microplate absorbance reader (TECAN) at 540 nm.
2.9. Determination of protein level
The Lowry assay (Lowry et al., 1951) with some small modiﬁcations
was used to measure the protein level, reﬂecting the amount of SH-
SY5Y cells per well in control cells or after exposure to acrylamide dur-
ing differentiation. The SH-SY5Y cells were seeded and treated in exact-
ly the same way as for the MTT assay until the protein determination.
After 3 or 6 days of exposure, the medium was removed and the cells
were washed with 100 μL of PBS. Afterwards, the cells were lysed in
70 μL of 0.1 M NaOH. Fifty microliters of cell lysate from each well
were transferred to a 96-well plate for protein determination. On the
day of the measurement, 2 mL of equal volume of 1% CuSO4 and 2%
Na2C4H4O6 (w/v) were added to 2 g of Na2CO3 and 0.4 g of NaOH in
100 mL Milli-Q® water. From this solution, 200 μL were added to each
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of Folin's reagent (diluted 1:4 in Milli-Q® water) were added to each
well and carefully shaken on a plate shaker for exactly 30 min in dark-
ness. The absorbance wasmeasured at 690 nmusing a Sunrise™micro-
plate absorbance reader (TECAN).
2.10. 3H-Thymidine incorporation proliferation assay
The SH-SY5Y cells were seeded and treated in exactly the sameway
as for the MTT and the Lowry assay. Twenty-four hours before harvest-
ing, the cells were incubated with 1 μCi/well of 2 Ci/mmol, 1 mCi/mL
[methyl-3H]-thymidine. After 3 or 6 days of exposure, the medium
was removed and the cells were washed 2 times with 100 μL of PBS. Af-
terwards, the cells were lysed in 100 μL of hypotonic buffer containing
NP-40 for 30 min on ice during gentle shaking. The lysates were har-
vested on to a glass ﬁber ﬁlter, washed with PBS and left to dry at
room temperature. Once dry, the ﬁlters were collected in scintillation
vials and covered with 3 mL of scintillation ﬂuid. The samples were an-
alyzed using a Packard tri-carb liquid scintillation analyzer (PACKARD).
2.11. Real-time reverse transcription polymerase chain reaction
The C17.2 cells were seeded in 6 cm diameter culture dishes at a
density of 3.7 × 103 cells/cm2. Twenty-four hours after seeding, theme-
dium was changed to differentiation medium. At the same time, 10 or
100 μM of acrylamide was added to the exposed cells. The medium
was changed every 3 days. After 6 and 10 days the cells were harvested
by trypsinization and cell pellets were collected. Cells were centrifuged
for 5min at 500 g and the pelletwas stored at -80 °C until mRNA extrac-
tion. On the day of the experiment, the cells were lysed and mRNAwas
extracted using the Qiagen RNeasy Plus Mini Kit according to
manufacturer's instructions. The mRNA concentration in each sample
was determined by using a NanoPhotometer™ P-class (IMPLEN
GmbH). To assess RNA integrity, samples were prepared together with
sample buffer from the RiboRuler High Range RNA ladder kit and sepa-
rated on a 1% agarose gel containing 18% of a 37% formaldehyde solution
for approximately 2 h at 110 V. The gel was photographed using
ChemiDoc™ XRS+ (Bio-Rad) and the results were analyzed by using
the Image Lab 3.0 software program. Two μg of each sample were re-
verse transcribed into cDNA using oligo (dT)18 primer and RevertAid
™ H Minus First Strand cDNA Synthesis Kit. Real-time qPCR reactions
were carried out as described before (Lundqvist et al., 2013) in an iCycler
iQ5™machine (Bio-Rad) using Maxima® SYBR Green/Fluorescein qPCR
Master Mix. The samples were normalized against the reference gene
TATA box binding protein (TBP). The following primer sequences were
used; TBP 5′-GAATTGTACCGCAGCTTCAAAA-3′ (forward) and 5′-AGTG
CAATGGTCTTTAGGTCAAGTT-3′ (reverse), βIII-tubulin 5′-CAGGCCCGA
CAACTTTATCT −3′ (forward) and 5′-CTCTTTCCGCACGACATCTA-3′
(reverse), GFAP 5′-GATCGCCACCTACAGGAAAT-3′ (forward) and 5′-
GGATCTGGAGGTTGGAGAAA-3′ (reverse).
2.12. Western blot
The C17.2 cells were seeded in 10 cm diameter culture dishes at a
density of 3.7 × 103 cells/cm2. Twenty-four hours after seeding, theme-
dium was changed to differentiation medium. At the same time, 10 or
100 μM of acrylamide was added to the exposed cells. The medium
was changed every 3 days. The SH-SY5Y cells were seeded in 10 cm di-
ameter culture dishes at a density of 12.5 × 103 cells/cm2. Twenty-four
hours after seeding, the medium was changed to differentiation medi-
um. At the same time, acrylamide in ranging concentrations between
1 pM-1000 μM was added to the exposed cells. As for the C17.2 cells,
the medium was changed every 3 days. After 6 and 10 days for the
C17.2 cells and 3 and 6 days for the SH-SY5Y cells, the cells were lysed
in a hypotonic buffer containing NP-40 and 20–30 μg of the protein ly-
sate, determined by the Bradford assay according to manufacturer'sinstructions, were separated in a 10% SDS- polyacrylamide gel. The pro-
teinswere transferred to nitrocellulosemembranes and incubated over-
night at 4 °C with rabbit anti-βIII-tubulin (1:5000) or rabbit anti-GFAP
(1:1000) primary antibodies. Horseradish peroxidase-conjugated anti-
rabbit IgG (1:50,000 for GFAP and 1:3000 for βΙΙΙ-tubulin) was used as
secondary antibody. Goat anti-β-actin (1:5000) was used as a loading
control for C17.2. Horseradish peroxidase-conjugated anti-goat IgG
(1:3000) was used as secondary antibody for β-actin. The membranes
were developed using ChemiDoc™ XRS+ image system (Bio-Rad)
and the results were analyzed by using the Image Lab 3.0 software pro-
gram (Bio-Rad).
2.13. Immunoﬂuorescence microscopy
The C17.2 cells were seeded on glass coverslips (VWR collection,
VWR International, Stockholm, Sweden) in 24-well plates at a density
of 1.47 × 103 cells/cm2. Twenty-four hours after seeding, the medium
was changed to differentiation medium. At the same time, 10 or
100 μM of acrylamide was added to the exposed cells. The medium
was changed every 3 days. After 6 and 10 days, the medium was re-
moved and the cells were ﬁxed in ice cold 100% MeOH for 5 min at
room temperature, permeabilized in 0.5% Triton X-100 in PBS for
10 min and blocked for 10 min in AbDil (0.1% Triton- X 100 in buffer
for immunoﬂuorescence staining of cytoskeletal proteins [10 mMMES
pH 6.1, 138mMKCl, 3mMMgCl2, and 2mMEGTA, 0.32M sucrose] sup-
plemented with 2% BSA and 0.1% azide dilution). Abdil was stored at 4 °
C and the sucrose was added on the day of the experiment. The cells
were incubated overnight at 4 °C with primary antibodies rabbit, i.e.
anti-GFAP (1:100) or rabbit anti-βΙΙΙ tubulin (1:1000) in AbDil. Anti-
rabbit conjugated with AlexaFluor488 (1:2500) in PBS 2% BSA was
used as a secondary antibody and nuclei were stained with DRAQ5
(1:10,000) in AbDil. The coverslips were mounted on slides with
SouthernBiotech Fluoromount-G™ and left to dry overnight. The immu-
noﬂuorescence was visualized with a ﬂuorescence microscope Leica
DM/IRBE 2. Images were taken with Hamamatsu Orca ER CCD camera
and analyzed byMicro-Manager (Edelstein et al., 2010) and ImageJ soft-
ware program.
2.14. Ratio of different cell populations
The immunoﬂuorescence images were used to calculate the ratio of
βIII-tubulin positive cells and the βIII-tubulin negative cells, i.e. the pro-
genitor cells and the astrocytes. For each image, the total number of
DRAQ5 stained nuclei and the number of βIII-tubulin positive cells
was calculated. The remaining cells were considered as the βIII-tubulin
negative cells. Two images were depicted for each biological replicate
and the mean value for each situation was calculated. The mean value
was considered as one n. The number of nuclei counted for each picture
was between 100 and 200, depending on the concentration of acrylam-
ide exposure. The statistical analysis for this experiment was based on
n= 3, i.e. 3 individual experiments.
2.15. Morphological evaluation
C17.2 cells were seeded and treated as for the western blot experi-
ment. After 6 and 10 days the cells were photographed using a phase
contrast microscope (Olympus). Microscopy images were captured at
200× magniﬁcation using a CCD camera (Olympus DP50).
2.16. Neurite outgrowth
C17.2 cells were seeded in 6-well plates at a density of
1.47 × 103 cells/cm2. Twenty-four hours after seeding, the medium
was changed to differentiation medium. At the same time, acrylamide
was added to the exposed cells in a range from 100 nM to 100 μM.
SH-SY5Y cells were seeded in 6-well plates at a density of
Fig. 1. The effect of acrylamide on proliferation and the number of viable cells in
undifferentiated C17.2. A) Number of C17.2 cells after exposure to 10, 100 or 1000 μM
acrylamide. The arrow indicates the start of exposure. The data are presented as the
mean of 5 independent experiments performed in duplicates. B) Viability of the C17.2
cells after 3 days of acrylamide exposure at different concentrations. The data are
presented as the mean of 4 independent experiments performed in hexaplicates. C) Cell
proliferation displayed as BrdUrd positive cells and cell death displayed as Sub-G1
region after 3 days of acrylamide exposure at different concentrations. The data are
presented as the mean of 3 independent experiments. Results were analyzed using one-
way ANOVA followed by Fischer's LSD test. A–C) Bars represent the mean ± SEM.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared to control (cells exposed to medium without
acrylamide).
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changed to differentiation medium. At the same time, acrylamide was
added to the exposed cells in a range from 1 pM to 100 μM. Themedium
was changed every 3 days for both cells lines. Each seed out consisted of
biological duplicates (i.e. twowells per situation). After 3 and 6 days for
the SH-SY5Y cells and 6 and 10 days for the C17.2 cells, the cells were
photographed using a phase contrast microscope (Olympus). Microsco-
py images were captured at 150× magniﬁcation using a CCD camera
(Olympus DP50). Cell bodies and neurites that were longer than the di-
ameter of the cell body were counted and the number of neurites per
cell was estimated as previously described (Nordin-Andersson et al.,
1998). For the C17.2 cell line, the images were also used to determine
the percentage of neurons in the cell culture. Two pictures were taken
for each biological replicate and the mean value for each situation was
calculated. The mean value was considered as one n. The number of
cell bodies counted for each picture was between 60 and 120, depend-
ing on the concentration of acrylamide exposure. The statistical ana-
lyzes for this experiment was based on n = 3, i.e. 3 individual
experiments, each performed in duplicates.
2.17. Statistical analysis
GraphPad Prism 6.0 was used for statistical analysis of the data. Re-
sults were analyzed using one- or two-way ANOVA followed by
Fischer's LSD test, *p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 as compared to
control.
3. Results
3.1. Acrylamide affects proliferation of neural progenitor and neuroblasto-
ma cells
Duringtheinitialphaseofbraindevelopmentthereisanexpansionof
neuralprogenitorcells. Studyingtheproliferationofundifferentiated
neuronalandglialprecursorscanbeusedasamodeltomimictheexpan-
sionofprogenitorcellsandhence,theproliferativestageofneuraldevel-
opment (Jaaro-Peled et al., 2009). Fig. 1A shows that, during 48 h of
exposureto1000μMofacrylamide, theproliferationwassigniﬁcantly
reducedintheundifferentiatedneuralprogenitorcellsC17.2.Intheun-
differentiatedneuroblastomaSH-SY5Ycells,exposureto1000μMofac-
rylamidereducedthenumberofviablecells totheextentofbeingeven
fewer cells thanwere initially seeded in the cell culture dishes (Fig.
2A).After72hofexposureto100μMofacrylamide,thenumberofundif-
ferentiatedC17.2cellswassigniﬁcantlyreduced.Thenumberofviable
cells in thetwoundifferentiatedcell lineswasmeasuredwiththeMTT
assay after 3days of acrylamide exposure (Figs. 1B and2B). Both cell
linesshowedthat750μMofacrylamidesigniﬁcantlyreducedthenum-
berofviablecellsat this timepoint.FortheSH-SY5Ycells,whichcanbe
grownforalongertimewithoutspontaneouslydifferentiatingorunder-
goingapoptosis,theviabilitywasalsomeasuredafter6daysofexposure.
Prolongedexposureshowedasigniﬁcantreductioninthenumberofvi-
ablecells, i.e.decreasedformazanformation,alreadyat250μMofacryl-
amideincomparisonwithcontrolcells.Forbothcelllines,thereduction
incellnumberandcellviabilityduringacrylamideexposurewasduetoa
combinationofbothreducedcellproliferationandincreasedcelldeath
(seen in Fig. 1C for the C17.2 cell line and in Fig. 2C and D for the SH-
SY5Y cell line). For both cell lines, cell death (analyzed as sub-G1)
seemstooccurat lowerconcentrationsascomparedtotheattenuated
cell proliferation, i.e. reduction inBrdUrdpositivecells. These results
showthatacrylamideaffectscellproliferationandinducecelldeath in
undifferentiatedneuralprogenitor cells andneuroblasts. It alsopin-
points the fact that the toxicityofacrylamide iscorrelatedtoduration
of exposure. Thecell cyclephaseswereanalyzedafterPI stainingbut
didnotrevealanysigniﬁcantchanges.However,therewasaslightindi-
cationofaG0/G1-blockafteracrylamideexposure(datanotshown).3.2. Acrylamide affects neuronal differentiation and the viability of differen-
tiating nerve cells
Both cell lines were exposed to a wide range of acrylamide concen-
trations throughout 6 and 10 days of differentiation for the C17.2 neural
Fig. 2. The effect of acrylamide on proliferation and the number of viable cells in undifferentiated SH-SY5Y. A) Number of SH-SY5Y cells after exposure to 10, 100 or 1000 μM acrylamide.
The arrow indicates the time of exposure. The data are presented as themean of 5 independent experiments performed in duplicates. B) Viability of the SH-SY5Y cells after 3 or 6 days of
acrylamide exposure. The data are presented as themean of 4 independent experiments performed in hexaplicates. C) and D) Cell proliferation displayed as BrdUrd positive cells and cell
death displayed as Sub-G1 region after 3 and 6 days respectively, of acrylamide exposure at different concentrations. The data are presented as the mean of 3 independent experiments.
Results were analyzed using two-way ANOVA followed by Fischer's LSD test. A–D) Bars represent themean± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared to control (cells exposed to
medium without acrylamide).
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toma SH-SY5Y cells. The different durations of exposure were used to
reﬂect different exposure windows during neurodevelopment. The
amount of viable cells was measured after the same time points using
the MTT assay. Acrylamide signiﬁcantly reduced the number of viable
C17.2 cells during differentiation in a time- and concentration-depen-
dent manner, starting at 100 μM during 6 days of exposure and at
10 μM during 10 days of exposure (Fig. 3). The number of viable SH-Fig. 3. The effect of acrylamide on the number of viable C17.2 cells after 6 and 10 days of
differentiation determined by the MTT reduction assay. Data are presented as the mean
of 5 independent experiments performed in hexaplicates. Results were analyzed using
two-way ANOVA followed by Fischer's LSD test. The bars represent the mean ± SEM.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared to control (cells exposed to medium without
acrylamide).SY5Y cells signiﬁcantly increased during 6 days of exposure to 10 pM–
10 μM of acrylamide, followed by a decrease during 3 and 6 days of ex-
posure to 100 μM or higher concentration (Fig. 4A). To conﬁrm that the
increase inMTT reduction reﬂected the amount of viable cells as a result
of increased cell proliferation rather than increased metabolic rate, the
3H-thymidine incorporation proliferation assay was performed (Fig.
4B). The assay followed the same trend as the MTT viability assay and
displayed a signiﬁcant increase in 3H-thymidine incorporation for con-
centrations between 1 fM–10 μM, followed by a decrease in 3H-thymi-
dine incorporation at higher concentrations. The total cellular protein
concentrationwas determined in the same experimental setup. The cel-
lular protein concentrations followed the same trend as theMTT viabil-
ity assay and the 3H-thymidine incorporation assay (Fig. 4C). Taken
together, these results manifests that very low concentrations of acryl-
amide increased the number of cells due to increased proliferation and
that higher concentration than 500 μM induced cytotoxicity and results
in a decrease in cell number in comparison to unexposed control cells.3.3. Acrylamide changes the expression of biomarkers for neuronal and glial
cell differentiation in C17.2 cells
Oneway of studying neuronal and glial differentiation is to study the
expression levels of mRNA and protein biomarkers that are signiﬁcant
for differentiation. βIII-Tubulin is a biomarker for semi-mature neurons
(Menezes and Luskin, 1994) and it was selected as the biomarker for
neuronal differentiation. Glial ﬁbrillary acidic protein is the most com-
monly used biomarker for astrocytes (Bramanti et al., 2010) hence it
was used as indicator of astrocytes in the differentiated C17.2 cell cul-
tures (Lundqvist et al., 2013).
Fig. 4. The effect of acrylamide on the number of viable cells and proliferation of SH-SY5Y
cells during 3 and 6 days of differentiation. A) Cell viability determined by the MTT
reduction assay. B) 3H-thymidine incorporation proliferation assay. C) Protein
determination by the Lowry assay. For all experiments, the data are presented as the
mean of 3–5 independent experiments each performed in hexaplicates. Results were
analyzed using two-way ANOVA followed by Fischer's LSD test. The bars represent the
mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared to control (cells exposed to
medium without acrylamide).
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mRNA level and signiﬁcantly reduced the protein level of βIII-tubulin
(Fig. 5A and B). The same trendwas seen for GFAP, where 100 μMof ac-
rylamide exposure for 10 days signiﬁcantly reduced themRNA and pro-
tein levels (Fig. 5C and D). No signiﬁcant change in mRNA or protein
expression of neither βIII-tubulin, nor GFAP was observed after 6 days
of exposure (Fig. 5). The attenuated biomarker expressionwas also con-
ﬁrmed by immunoﬂuorescencemicroscopy. By looking at the immuno-
ﬂuorescence of βIII-tubulin-positive cells after exposure to 10 μM and
100 μM acrylamide, it was clear that the population was reduced (Fig.6A-C). This was conﬁrmed by calculating the ratios for the two different
cell populations i.e. βIII-tubulin positive cells representing the neuronal
cell population and βIII-tubulin negative cells representing the progen-
itor and the astrocytic cell populations (Fig. 6K). The fraction of βIII-tu-
bulin positive cells decreased while the fraction of βIII-tubulin negative
cells increased. The number of neurons was signiﬁcantly reduced after
exposure to 1 μM of acrylamide (Fig. 6J). Interestingly, although the
number of neurons decreased, the numbers of neurites per cell was
not affected by acrylamide exposure in the C17.2 cell line (Fig. 6J). The
phase contrast images (Fig. 6G-I) further display that the cell cultures
consisted of two distinctly different morphological phenotypes. The
neurons grew on top of the astrocytes and it was possible to see that ac-
rylamide exposure reduced the fraction of neurons in differentiating
C17.2 cells. Acrylamide exposure also reduced the ﬂuorescence intensi-
ty for theGFAP-positive cell population (Fig. 6D-F). Thus, acrylamide re-
duced the levels of both the neuronal and the glial biomarker during
differentiation of the multipotent neural progenitor C17.2 cells.
3.4. Acrylamide impairs neurite outgrowth and βIII-tubulin expression in
differentiating SH-SY5Y neuroblastoma cells
The SH-SY5Y cell line is a commonly used cell model for studying
neurite degeneration and neurite outgrowth (Nordin-Andersson et al.,
2003). In this experiment, the SH-SY5Y cells were exposed to acrylam-
ide during differentiation, and after 3 and 6 days the number of neurites
per cell was evaluated. The number of neurites was signiﬁcantly re-
duced after 6 days of exposure to 10 pM of acrylamide and by 100 nM
after 3 days of exposure (Fig. 7). Taken together, acrylamide impairs
neurite outgrowth in the SH-SY5Y cell line during differentiation in a
time- and concentration-dependent manner. To further investigate
how the differentiation process was affected by acrylamide exposure
we measured the level of βIII-tubulin with western blot. As mentioned
above, βIII-tubulin is a biomarker for semi-mature neurons. Acrylamide
exposure slightly reduced the level of βIII-tubulin in differentiating SH-
SY5Y cells after 3 and 6 days of differentiation (Fig. 7J).
4. Discussion
People are exposed to acrylamide throughout their lifespan, starting
in utero. After birth, the exposure to acrylamide continues via the breast
milk, intake of food and drinks, but also from the environment. In this
study, concomitantly with several earlier studies (reviewed by
(LoPachin, 2004)), it was shown that the neurotoxic effects of acrylam-
ide are concentration-dependent and also accumulate over time. It
seems like it is not the accumulation of acrylamide itself, but rather
the accumulation of damages over prolonged exposure time that leads
to neurotoxicity (Crofton et al., 1996). With this in mind, it raises the
question about the developmental consequences of prenatal acrylamide
exposure and what the tolerated daily intake of acrylamide is during
pregnancy. In the WHO report from 2005, it was estimated that the av-
erage consumption of acrylamide was 0.8–3 μg acrylamide/kg/day for
adults. However, the consumption in children was estimated to be 2–
3 times higher when expressed as a body weight ratio (World Health
Organization, 2005). Aside from the fact that children eat higher
amount of food relative to their size, foodstuff containing relatively
higher levels of acrylamide is also preferred by children e.g. cereal,
French fries and potato chips (Cengiz and Gündüz, 2013). In this study
we show that acrylamide-induced effects on early phases of
neurodevelopment, such as the expansion of neural progenitor cells
and neuroblasts, but also during the differentiation process affecting
biomarkers for neural differentiation and axonal outgrowth. We show
that acrylamide impaired neural differentiation in the SH-SY5Y cell
line at nine orders of magnitude and in the C17.2 cell line at two orders
of magnitude lower concentration than previously reported for other
neural cell systems (Chen and Chou, 2015, Sisnaiske et al., 2014). The
previous studies displayed signiﬁcant effects of acrylamide on
Fig. 5. The effect of acrylamide on the expression levels of biomarkers for neurons and astrocytes in the C17.2 cell line. The cells were exposed to either 10 μM or 100 μM of acrylamide
during the differentiation for 6 or 10 days. A) mRNA level of β-III tubulin during differentiation and acrylamide exposure. B) mRNA level of GFAP during differentiation and acrylamide
exposure. C) Protein levels of β-III tubulin during differentiation and acrylamide exposure. D) Protein levels of GFAP during differentiation and acrylamide exposure. E) Representative
western blot staining for β-III tubulin, GFAP and the loading control β-actin. The data from mRNA expression levels were normalized against the reference gene TBP and are presented
as the mean of 4 independent experiments performed in duplicates. The data from the protein levels were normalized to β-actin and presented as the mean of 3 independent
experiments performed in duplicates. Results were analyzed using one- or two-way ANOVA followed by Fischer's LSD test. Bars represent the mean ± SEM. *p ≤ 0.05, **p ≤ 0.01,
compared to control (cells exposed to medium without acrylamide).
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tration of acrylamide, which has been reported to be around 1 mM
(Nordin-Andersson et al., 2003, Cody et al., 2013). It also raises a ques-
tion about the physical relevance of the previously tested concentra-
tions. There are only few reports on the plasma level of acrylamide in
the general population, but a study on exposed workers showed that
the unexposed control group had a concentration of free acrylamide in
plasma of approximately 1 μM (Calleman et al., 1994). With the placen-
tal transfer of acrylamide being around 20% (Sörgel et al., 2002), a rough
estimation indicates that the fetus might be exposed to an acrylamide
concentration around 0.2 μM. Our results show that in one of the cell
lines, SH-SY5Y, acrylamide induced signiﬁcant effects on differentiation
starting at 10 fM, which is seven orders ofmagnitude lower than the es-
timated plasma concentration of free acrylamide in the fetus.
For the undifferentiated cells, acrylamide reduced the number of vi-
able cells in both cell lines. By performing assays for both proliferation
and cell death, we could conclude that the reduction in viability seen
from the MTT assay was caused by a combination of cell death and re-
duced proliferation in both cell lines (Figs. 1 and 2). However, it seemslike cell death occurs at lower concentrations thanwhat affects cell pro-
liferation. Comparing the two cell lines, it seems like the neural progen-
itor cells are slightly more sensitive to acrylamide exposure after 3 days
of exposure, showing signiﬁcant increase in cell death starting at
500 μM. As mentioned above, the physiological relevance of these con-
centrations can be questioned. However, one should keep in mind that
the exposure scenario is far shorter in vitro than the chronic exposure
that the fetus is exposed to in the uterus and that acrylamide toxicity
is closely linked to the duration of exposure.
The SH-SY5Y cells undergo differentiation and become post-mitotic
when exposed to all-trans-retinoic acid (Påhlman et al., 1990). TheMTT
reduction assay and the protein concentration were measured after ex-
posing the SH-SY5Y cells to acrylamide during differentiation (Fig. 4).
Both assays showed that low concentrations of acrylamide (1 pM–
10 μM) increased the number of viable cells as well as the protein con-
centration. The 3H-thymidine incorporation assay was performed with
the same experimental setup as the two previous assays to see if the in-
crease inMTT reduction andprotein concentrationwas due to increased
proliferation. The 3H-thymidine incorporation assay conﬁrmed that the
Fig. 6. The effect of acrylamide on neurons and astrocytes in differentiating C17.2 cells. The cells were exposed to either 10 μMor 100 μM of acrylamide during differentiation for 10 days.
Immunoﬂuorescence images of the level of β-III tubulin (green) A) in control cells, B) cells exposed to 10 μM and C) cells exposed to 100 μM. Immunoﬂuorescence images of the level of
GFAP (green) inD) control cells, E) cells exposed to 10 μMand F) cells exposed to 100 μM.Nucleiwere stained in bluewithDRAQ5. Phase contrast image of G) control cells, H) cells exposed
to 10 μMand I) cells exposed to 100 μMof acrylamide. The scale bars represent 50 μminall images. J)Number of neurons and number of neurites per cell after 10 days of differentiation and
acrylamide exposure. K) Ratios of the different cell populations after 10 days of differentiation and acrylamide exposure. Statistical signiﬁcance is based on comparison to the control for
each respective cell population. The data are presented as the mean of 3 independent experiments performed in duplicates. Results were analyzed using two-way ANOVA followed by
Fischer's LSD test. The bars represent the mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared to control (cells exposed to medium without acrylamide).
108 K. Attoff et al. / Toxicology in Vitro 35 (2016) 100–111SH-SY5Y cells, although exposed to all-trans-retinoic acid, increased the
proliferation compared to control when exposed to low concentrations
of acrylamide (Fig. 4B). In the control situation, the differentiation pro-
cess in the SH-SY5Y cells begins at the start of all-retinoic-acid exposure.
However, the entire cell population is not synchronized in the cell cycle.
Hence, some cells enroll the differentiation process before others. Acryl-
amide seems to attenuate the differentiation process into post-mitotic
neurons, resulting in increased proliferation giving an increasednumber of cells. In conclusion, concentrations lower than 10 μM did
not seem to display any cytotoxicity but attenuated the differentiation
process in neurons. No increase in the number of cells during exposure
to low concentrations of acrylamide as compared to control cells was
observed in the C17.2 cell line (Fig. 3). This may be explained by several
observations. Firstly, the C17.2 cell line consisted of several different cell
populations. The proliferation of a population of the progenitor cells,
probably astrocyte precursors, proceeded during differentiation even
Fig. 7. The effect of acrylamide on the neurite outgrowth in differentiating SH-SY5Y cells. Cells differentiated for 3 days during exposureA)without acrylamide, B)with 1 μMof acrylamide,
C) with 10 μM of acrylamide or D) with 100 μM of acrylamide. Cells differentiated for 6 days during exposure E) without acrylamide, F) with 1 μM of acrylamide, G) with 10 μM of
acrylamide or H) with 100 μM of acrylamide. The scale bars represent 50 μm in all images. I) Number of neurites per cell after 3 and 6 days of differentiation and acrylamide exposure.
The data are presented as the mean of 3 independent experiments, each seed out consisted of biological duplicates. Bars represent the mean of each biological duplicate ±SEM.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared to control (cells exposed to medium without acrylamide). J) Protein levels of β-III tubulin during differentiation and acrylamide exposure.
The data is presented as the mean of 4 independent experiments. Results were analyzed using two-way ANOVA followed by Fischer's LSD test. Bars represent the mean ± SEM.
*p ≤ 0.05, *p ≤ 0.05, **p ≤ 0.01, compared to control (cells exposed to medium without acrylamide).
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in the cultures, an increase in proliferation in this smaller cell population
(neurons) would be harder to detect above the background noise. Sec-
ondly, the two cell lines were differentiated via different pathways.
The attenuation of differentiation in the SH-SY5Y cells might be a result
from acrylamide interfering with the all-trans-retinoic acid signaling
and hence, would not affect the differentiation of C17.2 cells in the
same way. Acrylamide have been shown in previous studies to change
the expression and status of different MAP kinases (Duan et al., 2015).
All-trans-retinoic acid signals through retinoic acid receptors and reti-
noid X receptors in retinoic acid mediated transcription. A subset ofretinoic acid receptors signals through MAP kinases (Piskunov and
Rochette-Egly, 2012) and acrylamide interference with these kinases
could result in aberrant transcription of differentiation related genes.
Thirdly, the C17.2 cell cultures consisted of a mixed culture of neurons
and astrocytes. Astrocytes have a pivotal role in the function of neurons.
Astrocytes possess somemetabolic capacity thatmay affect the concen-
tration of acrylamide (Sagara and Sugita, 2001). Furthermore, astrocytes
synthesize and secrete a wide range of cytokines, neurotrophic factors,
growth factors, proteoglycans, extracellularmatrix proteins and choles-
terol that are involved in neuronal proliferation, differentiation, synap-
togenesis and survival (Blondel et al., 2000). These factors might
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rylamide exposure. However, the number of neurons decreased in the
C17.2 cell cultures during acrylamide exposure. Although the neurotox-
ic concentrationswere not as low as for the SH-SY5Y cells, there was at-
tenuated differentiation of the neuronal precursor population also in
the C17.2 cell culture starting at 1 μM of acrylamide exposure (Fig.
6J,K). For both cell lines, higher concentrations, starting at 10 μM for
C17.2 cells and 100 μM for SH-SY5Y cells, reduced the number of viable
cells and showed signs of cytotoxicity. Again, the differentiating C17.2
and SH-SY5Y cell models were more sensitive to acrylamide than
other neuronal cell models, here regarding cytotoxicity (Chen et al.,
2014, Walum and Flint, 1993).
Axonal outgrowth was affected by acrylamide in the SH-SY5Y cell
line. There was a reduction in the number of neurites per cell in the
SH-SY5Y cells, starting at a concentration of 10 pM of acrylamide (Fig.
7), which is an indication of a less differentiated neuronal cell culture.
These results further strengthen the observation of increased prolifera-
tion and attenuated differentiation seen in Fig. 4. The inhibition or delay
of axonal outgrowth might be due to conjugation of acrylamide to
neuroﬁlaments and components of the microtubular system that are
important for proper axonal function (Tandrup and Jakobsen, 2002).
Furthermore, it could also be a consequence of the multiple possible
conjugation-targets of acrylamide in the nerve terminal (Barber et al.,
2007). The attenuated neuronal differentiation in the SH-SY5Y cell line
was also observed when looking at the levels of βIII-tubulin (Fig. 7J),
which was slightly reduced during acrylamide exposure. The fact that
there was less difference seen after 6 days of differentiation compared
to 3 days might be explained by the fact that βIII-tubulin is a biomarker
for semi-mature neurons, and is not as signiﬁcantly expressed in more
mature cultures.
Both the βIII-tubulin-positive cell population and the GFAP-positive
cell population were reduced by 100 μMof acrylamide exposure during
differentiation. The reduced mRNA expression of both biomarkers indi-
cates that acrylamide did not only change the protein levels of these bio-
markers, but also had an effect at the transcriptional level of gene
expression (Fig. 5A and C). It should be noted, though, that 100 μM ac-
rylamide generated approximately 15% reduced number of viable
cells. Acrylamide exposure decreased the number of neurite-bearing
C17.2 progenitor cells when looking at the immunoﬂuorescence stain-
ing with βIII-tubulin and also the phase contrast images (Fig. 6). How-
ever, the number of neurites per cell was not affected by acrylamide
exposure. One explanation between the differences seen by the two
cell lines might be that the astrocytes in the mixed C17.2 cell culture
can buffer some of the neurotoxicity, e.g. by providing other conjuga-
tion-sites for acrylamide such as glutathione (Kurebayashi and Ohno,
2006). Also, the neurons in the C17.2 cell culture grew on top of the as-
trocytes providing neurotrophic support, whereas the SH-SY5Y cells
grew directly on the tissue culture treated plastic. One should alsomen-
tion that the two different cell lines are derived from two different spe-
cies, giving rise to possible interspecies differences. The two cell lines
also derived from two different origins of the nerve system; the neural
progenitor cells were isolated from cerebellum and the neuroblastoma
cells derived from the neural crest. As mentioned above, their differen-
tiation processes might differ in the sense of what receptors and path-
ways are involved.
In conclusion, our results indicate that acrylamide affected both pro-
liferation and differentiation in two different neuronal cell models. The
fact that acrylamide seemed to attenuate differentiation at low concen-
trations raises questions about possible developmental neurotoxicity.
The incidence of children being diagnosed with disorders that are asso-
ciated with impaired cognition is increasing. A report from the National
Academy of Sciences states that 28% of all major developmental disor-
ders in children are linked entirely or partly to environmental exposures
(National Research Council, 2000). Three percent of these being a direct
result of environmental exposure to chemicals and the other 25% arise
from interactions between environmental factors and speciﬁc geneticfactors, making that particular individual susceptible (Grandjean and
Landrigan, 2006). The present study suggests and the differences be-
tween the two cell lines should be further evaluated in regards to
their sensitivities to acrylamide. The differencemight be able to provide
some insight to the toxicological mechanism of acrylamide.
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